Founded in 1998, Seattle Genetics is a Biotechnology firm that specializes in the development and selling empowered, innovative antibody-based therapies that treat cancer. Headquartered in Washington, Seattle Genetics is the industry leader in the production of antibody-drug conjugates (ADCs), a technology developed to harness the targeting capacity of monoclonal antibodies to supply cell-destroying agents to cancer cells directly. ADCs are meant to spare the untargeted cells and hence reduce most of the toxic after-effects of the traditional chemotherapy while enhancing the antitumor activity at the same time.
The flagship of the company product, Brentuximab vedotin (Adcetris) is available commercially for two symptoms in 50 nations, including members of the European Union, Japan, Canada and the US. The approval of Adcetris makes the medication the first in a new classification of ADCs.
To extend Brentuximab vedotin’s clinical opportunities, Seattle Genetics is carrying out an extensive clinical development plan to assess its therapeutic potential regarding approved indications and its non-lymphoma and other lymphoma settings. The firm is jointly building Brentuximab vedotin with Takeda Pharmaceutical Company. Within the terms of this association, Seattle Genetics enjoy full commercialization rights to this drug in Canada and the United States.
Clay Siegal is a co-founder, Chief Executive Officer and the President of Seattle Genetics, and also the Chairman of the company’s Board. Trained as a scientist with a remarkable emphasis on targeted therapies for cancers, Dr. Clay Siegal established Seattle Genetics on the basis of rigorous research, drug development practices, scientific innovation as well as a desire to assist patients. He has directed the firm to its present leadership position in the development of antibody-drug conjugates and in acquiring the FDA approval in 2011 in its first ADC creation, Brentuximab vedotin or Adcetris. In partnership with Takeda Pharmaceuticals, Adcetris is currently a global product approved in over 65 countries. The company is also advancing the different pipeline of branded ADCs for cancer treatment.
Under the able leadership of Clay Siegal, Seattle Genetics has acquired multiple strategic permits for the ADC technology, including Pfizer, GlaxoSmithKline, AbbVie, and Genentech (Roche) which have generated over $350 million up to now. Across collaborator and internal programs, there are over 20 ADCs that are in clinical development utilizing the Seattle Genetics’ technology. Clay has also steered the capital-raising activities of Seattle Genetics securing over $1.2 billion through private and public financings, including the initial public offering of the company in 2001.
Dr. Siegal serves as a board member at Alder BioPharmaceuticals, a private-owned biotechnology company. He holds a Ph.D. in Genetics and a Bachelor’s degree in Zoology from George Washington University and the University of Maryland respectively. He is an author of over 70 publications and owns 15 patents.